Published in Blood Weekly, November 4th, 2004
"We expect to file for market authorization of our superior fenofibrate product in 2005, providing LifeCycle Pharma with its first launch," said Jan Møller Mikkelsen, president and CEO of LifeCycle Pharma. "LifeCycle Pharma has several products in clinical trials, but fenofibrate is the first that we advance into clinical trials independently of a partner," said Mikkelsen.
"In less than 12 months, we have developed a superior fenofibrate tablet formulation, from idea to clinical trials," said Michael...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.